PHILADELPHIA, Oct. 28, 2021 /PRNewswire/ -- Spirovant Sciences,
a gene therapy company developing treatments and cures for
inherited respiratory diseases including cystic fibrosis (CF),
today announced that it will be delivering oral and poster
presentations highlighting pre-clinical data for its compound,
SP-101, at the 2021 North American Cystic Fibrosis
Conference (NACFC 2021), November
2-5. SP-101, an investigational novel recombinant
adeno-associated virus (AAV) gene therapy selected for its tropism
to human airway epithelia, is being developed for inhalation in
patients with CF who do not benefit from treatment with Cystic
Fibrosis Transmembrane Conductance Regulator (CFTR) modulators,
which is approximately 20% of all patients with CF. Additional
details will be presented during the scheduled presentations.
Workshop Details
W05.5: Delivery of SP-101 restores CFTR function in human CF
airway epithelial cultures and drives hCFTRΔR transgene
expression in the airways of ferrets
November 3, 2021, 11:00 AM
- 1:00 PM ET
Presenter: Katherine Excoffon, Ph.D., VP, Research, Spirovant
Sciences
Presented During: W05--PTC-GMS: Approaches for Delivery of
Nucleotide Based Therapeutics
Poster Presentation Details
Delivery of
SP-101 restores CFTR function in human CF airway
epithelial cultures and drives hCFTRΔR transgene
expression in the airways of ferrets
November 4, 2021, 1:10 PM
ET
Presenter: Katherine Excoffon, Ph.D., VP, Research, Spirovant
Sciences
About Spirovant Sciences, Inc.
Spirovant is a gene
therapy company focused on changing the course of cystic fibrosis
and other respiratory diseases. The company's current
investigational gene therapy technologies are designed to overcome
the historical barriers that have prevented effective genetic
treatments for cystic fibrosis. Spirovant's lead programs are in
development for cystic fibrosis. Spirovant is a wholly-owned
subsidiary of Sumitovant Biopharma Ltd., which is itself a
wholly-owned subsidiary of Sumitomo Dainippon Pharma Co.,
Ltd. Spirovant is located in Philadelphia, PA. More
information is available at https://www.spirovant.com/.
About Sumitovant Biopharma Ltd.
Sumitovant is a
global biopharmaceutical company leveraging data-driven insights to
rapidly accelerate development of new potential therapies for unmet
patient conditions. Through our unique portfolio of wholly-owned
"Vant" subsidiaries—Urovant, Enzyvant, Spirovant, Altavant—and use
of embedded computational technology platforms to generate business
and scientific insights, Sumitovant has supported development of
FDA-approved products including GEMTESA®
for overactive bladder and RETHYMIC® for
pediatric congenital athymia, and has advanced a promising pipeline
of early-through late-stage investigational assets for other
serious conditions. Sumitovant is the majority-shareholder of
Myovant (NYSE: MYOV) whose marketed products include
ORGOVYX® for advanced prostate cancer and
MYFEMBREE® for uterine fibroids. Sumitovant
is a wholly-owned subsidiary of Sumitomo Dainippon Pharma. For more
information, please
visit https://www.sumitovant.com.
About Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo
Dainippon Pharma is among the top-ten listed pharmaceutical
companies in Japan, operating
globally in major pharmaceutical markets, including Japan, the U.S., China, and other Asian countries. Sumitomo
Dainippon Pharma is based on the merger in 2005 between Dainippon
Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd.
Today, Sumitomo Dainippon Pharma has more than 7,000 employees
worldwide. Additional information about Sumitomo Dainippon Pharma
is available through its corporate website
at https://www.ds-pharma.com/.
View original
content:https://www.prnewswire.com/news-releases/spirovant-to-present-sp-101-data-at-the-2021-north-american-cystic-fibrosis-conference-301411246.html
SOURCE Spirovant Sciences